Literature DB >> 18787882

Parkinson's disease-related disorders in the impulsive-compulsive spectrum.

Eric Ch Wolters1, Ysbrand D van der Werf, Odile A van den Heuvel.   

Abstract

In Parkinson's disease (PD), there is increasing evidence for disorders in the impulsive-compulsive spectrum, related to the disease itself, to the pharmacological management of this disease or to both. These disorders comprise dopamine deficiency syndrome (with immediate reward seeking behaviour), dopamine dependency syndrome (with addictive behaviour), dopamine dysregulation syndrome (with both addictive behaviour and stereotyped behaviour) and impulse control disorders (such as pathological gambling, compulsive shopping, binge eating and hypersexuality). These disorders are especially seen in PD patients with young age of onset, higher doses of antiparkinsonian drugs, pre-existent or current depression, pre-existing recreational drug or alcohol use, and high novelty seeking personality traits.Dopamine is not only implicated in voluntary movement control but also plays a significant role in the brain's reward system and the modulation of behaviours. Therefore, most if not all drugnaïve PD patients will suffer dysphoria, leading to mild immediate reward seeking behaviour as a consequence of the striatal dopaminergic denervation. In some of these patients, during treatment, this may even lead to the intake of increasing quantities of levodopa, above those required to adequately treat motor parkinsonism, with all characteristics of a dopamine dependence syndrome. These patients may develop plastic changes in the striatal matrix leading to hyperkinesia, caused by extracellular striatal dopaminergic fluctuations due to pulsatile dopamine replacement therapy. As soon as these changes are also seen in the striatal striosomes, in the framework of a dopamine dysregulation syndrome, stereotyped behaviours (punding) may occur (supposedly due to dorsal versus ventral striatal overactivity). Finally, impulse control disorders are suggested as being pure adverse side-effects of dopamine replacement therapy. Obsessive-compulsive behaviour (caused by ventral to dorsal overactivity) so far has not been described in PD patients.Treatment of impulse control disorders is related to the underlying pathology. In the case of an intrinsic dopamine deficiency syndrome, treatment with dopamine replacement therapy, especially levodopa, will help. In the multifactorial (intrinsic and extrinsic) dopamine dependency and dysregulation syndromes, addictive behaviour might best be helped by psychosocial strategies, and punding by continuous dopaminergic receptor stimulation (or amantadine), hypothesized to reduce the plastic changes-induced hypersensitization. The extrinsic impulse control disorders might be best treated by reducing or replacing dopamine receptor agonists.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18787882     DOI: 10.1007/s00415-008-5010-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  60 in total

1.  Repetitive behaviors in monkeys are linked to specific striatal activation patterns.

Authors:  Esen Saka; Claudia Goodrich; Patricia Harlan; Bertha K Madras; Ann M Graybiel
Journal:  J Neurosci       Date:  2004-08-25       Impact factor: 6.167

Review 2.  Does an imbalance between the dorsal and ventral striatopallidal systems play a role in Tourette's syndrome? A neuronal circuit approach.

Authors:  Henk J Groenewegen; Odile A van den Heuvel; Danielle C Cath; P Voorn; Dick J Veltman
Journal:  Brain Dev       Date:  2003-12       Impact factor: 1.961

Review 3.  Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions.

Authors:  G E Alexander; M D Crutcher; M R DeLong
Journal:  Prog Brain Res       Date:  1990       Impact factor: 2.453

4.  Punding and dyskinesias.

Authors:  Laura Silveira-Moriyama; Andrew H Evans; Regina Katzenschlager; Andrew J Lees
Journal:  Mov Disord       Date:  2006-12       Impact factor: 10.338

Review 5.  The role of dopamine in human addiction: from reward to motivated attention.

Authors:  Ingmar H A Franken; Jan Booij; Wim van den Brink
Journal:  Eur J Pharmacol       Date:  2005-10-26       Impact factor: 4.432

6.  Prevalence of repetitive and reward-seeking behaviors in Parkinson disease.

Authors:  V Voon; K Hassan; M Zurowski; M de Souza; T Thomsen; S Fox; A E Lang; J Miyasaki
Journal:  Neurology       Date:  2006-09-06       Impact factor: 9.910

Review 7.  Dopamine dysregulation syndrome in Parkinson's disease.

Authors:  Andrew H Evans; Andrew J Lees
Journal:  Curr Opin Neurol       Date:  2004-08       Impact factor: 5.710

8.  Predictors of impulsivity and reward seeking behavior with dopamine agonists.

Authors:  William G Ondo; Dejian Lai
Journal:  Parkinsonism Relat Disord       Date:  2007-08-16       Impact factor: 4.891

9.  Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy.

Authors:  Andrew McKeon; Keith A Josephs; Kevin J Klos; Kathleen Hecksel; James H Bower; J Michael Bostwick; J Eric Ahlskog
Journal:  Parkinsonism Relat Disord       Date:  2007-06-04       Impact factor: 4.891

10.  A review of compulsive buying disorder.

Authors:  Donald W Black
Journal:  World Psychiatry       Date:  2007-02       Impact factor: 49.548

View more
  25 in total

1.  Lesions of the medial prefrontal cortex cause maladaptive sexual behavior in male rats.

Authors:  Jon F Davis; Maarten Loos; Andrea R Di Sebastiano; Jennifer L Brown; Michael N Lehman; Lique M Coolen
Journal:  Biol Psychiatry       Date:  2010-03-26       Impact factor: 13.382

2.  Impulsive smoking in a patient with Parkinson's disease treated with dopamine agonists.

Authors:  Karina L Bienfait; Matthew Menza; Margery H Mark; Roseanne D Dobkin
Journal:  J Clin Neurosci       Date:  2010-02-19       Impact factor: 1.961

3.  Decision making, impulsivity, and addictions: do Parkinson's disease patients jump to conclusions?

Authors:  Atbin Djamshidian; Sean S O'Sullivan; Yanosh Sanotsky; Stephen Sharman; Yuriy Matviyenko; Thomas Foltynie; Rosanna Michalczuk; Iciar Aviles-Olmos; Ludmyla Fedoryshyn; Karen M Doherty; Yuriy Filts; Marianna Selikhova; Henrietta Bowden-Jones; Eileen Joyce; Andrew J Lees; Bruno B Averbeck
Journal:  Mov Disord       Date:  2012-07-20       Impact factor: 10.338

4.  Are You Morally Modified?: The Moral Effects of Widely Used Pharmaceuticals.

Authors:  Neil Levy; Thomas Douglas; Guy Kahane; Sylvia Terbeck; Philip J Cowen; Miles Hewstone; Julian Savulescu
Journal:  Philos Psychiatr Psychol       Date:  2014-06-01

5.  Clinical characteristics of impulse control and repetitive behavior disorders in Parkinson's disease.

Authors:  Juyeon Kim; Mijin Kim; Do Young Kwon; Woo-Keun Seo; Ji Hyun Kim; Jong Sam Baik; Seong-Beom Koh
Journal:  J Neurol       Date:  2012-08-15       Impact factor: 4.849

6.  Increased reflection impulsivity in patients with ephedrone-induced Parkinsonism.

Authors:  Atbin Djamshidian; Yanosh Sanotsky; Yuriy Matviyenko; Sean S O'Sullivan; Stephen Sharman; Marianna Selikhova; Ludmyla Fedoryshyn; Yuriy Filts; Jenny Bearn; Andrew J Lees; Bruno B Averbeck
Journal:  Addiction       Date:  2013-02-11       Impact factor: 6.526

Review 7.  Heterogeneity of reward mechanisms.

Authors:  A Lajtha; H Sershen
Journal:  Neurochem Res       Date:  2009-12-12       Impact factor: 3.996

8.  [Medical treatment of Parkinson's disease in elderly and multimorbid patients].

Authors:  I Lettow; J Röther
Journal:  Internist (Berl)       Date:  2014-06       Impact factor: 0.743

9.  Influence of conditioned reinforcement on the response-maintaining effects of quinpirole in rats.

Authors:  Gregory T Collins; James H Woods
Journal:  Behav Pharmacol       Date:  2009-09       Impact factor: 2.293

Review 10.  Impulse control disorders in Parkinson's disease: an overview from neurobiology to treatment.

Authors:  Emke Maréchal; Benjamin Denoiseux; Ellen Thys; David Crosiers; Barbara Pickut; Patrick Cras
Journal:  J Neurol       Date:  2014-05-14       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.